Knopp Biosciences LLC is a privately held company managing a portfolio of future milestone payments and product royalties
Knopp Biosciences LLC is a privately held company managing a portfolio of future milestone payments and product royalties. Founded in 2004, the company sold and/or spun off its two drug pipelines in 2022. Knopp’s clinical stage Kv7 platform, small-molecule treatments for epilepsy and other hyperexcitability disorders, was acquired by Biohaven Pharmaceuticals and is currently in late stage clinical trials.